Inclusion Criteria:  Previously undergone Roux-en-Y gastric bypass (RYGB) surgery at least 6 months prior to screening Previous diagnosis of post-bariatric hypoglycemia (PBH), requiring intake of oral carbohydrates. Body mass index (BMI) ≤ 40 kg/m2 Fasting plasma glucose between 72-106 mg/dL (4.0-6.0 mmol/l)  Exclusion Criteria:  History of hypersensitivity reactions to glucagon or dasiglucagon or any of the excipients History of insulinoma, pheochromocytoma, MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease. Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m2 or end-stage renal disease at screening Hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase ≥ 2.5 times the upper limit of normal (ULN) Active malignancy, except for basal or squamous cell skin cancers History of a cerebrovascular accident within 6 months prior to screening History of myocardial infarction, unstable angina, or revascularization within 6 months prior to screening. Congestive heart failure, New York Heart Association Class III or IV Concurrent administration of β-blocker therapy Clinically significant ECG abnormalities at screening